title: [Viral attenuation of labile blood products].
abstract: Viral inactivation is one of the possibilities to reduce the residual risk of blood products. It is now applied to all plasma derived products (PDP). Application of such techniques to labile blood products (LBP) is difficult for two main reasons: any method should inactivate cell-associated viruses and should avoid any injury of the cells constituting the active ingredient. Physical techniques may reduce the viral content of cellular BPL (leucodepletion, washing, gamma irradiation), but none of them is active enough to comply with the present requirements for efficacy. An important work has been dedicated to the development of virus photoinactivation techniques. They consist of the addition of a photoreagent followed by illumination at an appropriate wavelength which results in a photochemical reaction responsible for the viral inactivation. Treatment of platelet concentrates by psoralen derivatives and UV-A illumination significantly inactivate in vitro enveloped and naked viruses, free and cell-associated viruses and also sequences integrated in the viral genome. Recent progresses have led to these results without detectable functional alteration of platelets and mutagenicity. Viral inactivation of red blood cells yet did not reach the same level because hemoglobin does not allow the use of the photoreagent compounds applicable to platelet concentrates. Viral decontamination of fresh frozen plasma by solvent and detergent, active on enveloped viruses, has been used in France since 1992. Other techniques of comparable efficacy, have received an agreement in other countries. The research on viral inactivation of LBP could prove to be of great importance in the near future in bringing additional safety to patients not only for the residual viral risk but maybe also for the residual bacterial risk of LBP.
authors.affiliation: Groupe Atténuation virale des produits sanguins labiles, Société Française de Transfusion Sanguine.
authors.forename: G
authors.initials: G
authors.lastname: Folléa
authors.forename: P
authors.initials: P
authors.lastname: Hervé
authors.forename: G
authors.initials: G
authors.lastname: Andreu
authors.forename: J M
authors.initials: JM
authors.lastname: Bidet
authors.forename: D
authors.initials: D
authors.lastname: Boudard
authors.forename: B
authors.initials: B
authors.lastname: Dazey
authors.forename: L
authors.initials: L
authors.lastname: Noël
authors.forename: Y
authors.initials: Y
authors.lastname: Piquet
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D016913:Blood Component Transfusion / Q000592:standards*; D001792:Blood Platelets / Q000821:virology*; D004912:Erythrocytes / Q000821:virology*; D006801:Humans; D007962:Leukocytes / Q000821:virology*; D010777:Photochemistry; D010949:Plasma / Q000821:virology*; D011786:Quality Control
chemical_list: D000998:Antiviral Agents
vernacular_title: Atténuation virale des produits sanguins labiles.